Although second-generation drug-eluting stents (DES) have improved outcomes in percutaneous coronary interventions (PCIs), important unmet needs remain. Two symposia at EuroPCR 2015 focused on two challenging scenarios. First, patients with diabetes mellitus (DM) have generally inferior outcomes following PCI. The Cre8™ stent (manufactured by CID Spa, member of Alvimedica Group) has shown unique efficacy in subpopulations of patients with DM during clinical trials. A live case in a patient with diabetes illustrated the challenges of complex multivessel disease. Second, optimising stent selection towards devices that have demonstrated complete and early endothelialisation offers the potential to reduce the duration of dual antiplatelet therapy. The Cre8™ DES features a polymer-free platform and has been associated with low rates of in-stent thrombosis.
The use of second-generation polymeric metallic drug-eluting stents However, the most striking finding of this study was that the LLL in the subgroup with diabetes was comparable to that in the general study population, a finding that had not been seen with other DES. 4, 5 Results show that the Cre8™ was non-inferior to the EES and demonstrated non-significant superiority in the primary endpoint. In addition, the Cre8™ resulted in a lower LLL with a lower standard deviation, though without achieving statistical significance.
In conclusion, the ideal DES should combine safety with an increased DES efficacy. The Cre8™ DES has unique safety features (polymerfree structure, abluminal reservoir technology) and unique efficacy features (polymer-free structure and the amphilimus formulation), and is currently being tested in a large clinical programme. Data obtained so far suggest that the best application of Cre8™ seems to be the subset of patients with diabetes. n The primary aim of the intervention was to treat the long lesion of the LAD. The lesion was wired using regular wire then dilated using a 2.0 balloon. A long stent was used (Cre8™ 46 mm), which crossed the The patient was admitted with acute coronary syndrome (ACS) and 50-60 % stenosis in the LAD. The physician advised the patient that if a DES was used, he would do better than with BMS; that a secondgeneration DES is better than a first; that an EES has the most robust evidence of safety; and that he would be prescribed new antiplatelet drugs and statins. However, despite these interventions, he would remain at high risk of restenosis and adverse cardiovascular events.
A 3.0 mm x 15 mm second-generation DES (zotarolimus-eluting stent
[ZES]) was implanted. At 6-month follow up, the patient had stable angina.
A 3.5 mm x 15 mm paclitaxel-eluting balloon was utilised to treat the restenotic lesion and the patient was discharged after experiencing no further events. However, 3 months later, the patient was readmitted due to an ACS and he was treated with crush stenting with a DES. The patient mentioned at the beginning of the presentation returned 3 months later with restenosis and received a stent of the left main. This patient was enrolled into the RESERVOIR clinical trial and received an AES.
Dr Romaguera considered the causes of DES failure. Polymer-related inflammation is an important cause (see Figure 2 ). In addition, resistance to mammalian target of rapamycin (mTOR) inhibition is seen in patients with DM: a tenfold higher concentration of an mTOR inhibitor is needed in the diabetic cell to achieve similar inhibition to that seen in a non-diabetic one. 6 The Cre8™ AES has unique features, making it well suited to patients with diabetes (see Figure 2 ). Among these, the amphiphilic carrier, which is a fatty acid, is a major component. Fatty acids play a main role in DM; cardiac cells cannot use glucose for energy generation as they are forced to utilise fatty acids. There is therefore an overexpression of cell membrane transporters and increased fatty acid uptake. 7 The amphiphilic carrier utilises this mechanism to enhance drug delivery: more than 99 % of the drug is eluted to the vessel wall. The use of the Cre8™ stent should allow cessation of DAPT at 3 months and to continue with a single antiplatelet agent as well as oral anticoagulation. Closure of the left atrial appendage (LAA) was discussed as an option if an issue arises with triple therapy. n cardiovascular mortality, which is not offset by a reduction in cardiac mortality. It is worth mentioning that this could have been chance finding. In addition, prolonged DAPT has been associated with a 72 % risk of major bleeding. 9 Therefore extended duration DAPT is not routinely recommended following PCI with stent implantation, but without DAPT, the risk of stent thrombosis increases.
The principal causative factors of DES stent thrombosis are summarised in Figure 3 . 10 Of these, around 25 % are procedural-related issues, 36 % are DES safety-related issues and 34 % are DES efficacy-related issues.
In a case-controlled study of 54 cases and 35 controls, the presence of uncovered stent struts was associated with stent thrombosis after DES: with a RUTTS score exceeding 30, stent thrombosis was seen in 21.6 % of cases versus none in cases with a RUTTS score less than 30. 11 In terms of DES efficacy issues related to stent restenosis, a RCT showed that EES were comparable to sirolimus-eluting stents (SES) in terms of overall clinical efficacy and safety. 12 Therefore, optimising the choice of DES can reduce stent thrombosis by approximately 70 %.
The Cre8™ DES features a polymer-free platform to reduce the risk of inflammation associated with durable polymers and the breakdown products of absorbable biopolymers (see Figure 2) . A drug-delivery system, abluminal reservoir technology, utilises a formulation of sirolimus and a fatty acid, amphiphilic carrier. Sirolimus, an mTor inhibitor, is an immunosuppressant with antiproliferative and antimicrobial activity. In addition, it inhibits inflammatory cell activities and has high potency. The organic acid maintains sustained drug delivery; fatty acids are used to improve the transdermal delivery of numerous drugs. 13 The fatty acid also enhances drug stability, as well as increasing the bioavailability of the drug; cardiac fatty acid uptake is doubled in diabetic mouse models.
14 This results in an increased homogeneous drug distribution in diabetic cardiac cells. In addition, the bio inducer surface, a second-generation integral pure carbon coating, is designed to accelerate stent endothelialisation and strut coverage, thus reducing the risk of thrombosis. The Cre8™ DES is polymer-free, eliminating the disadvantages associated with durable polymers or their breakdown products.
To end the presentation, Professor Stella discussed his experience with implantation of the Cre8™ stent in the University Medical Centre, Utrecht. To date, 786 implantations have been performed, 372 with ACS and 414 with stable disease. All stable elective cases were treated with life-long aspirin and clopidogrel for 3 months; all ACS cases were treated with 12 months of DAPT. Outcomes to date have been excellent.
In patients presenting with stable disease: at 6 months, stent thrombosis was seen in only 0.2 % of patients and TLR in 1.2 %. These findings have led to a new study design; an investigator-initiated randomised two-centre study, RECre8, which is currently enrolling, aims to recruit around 1,530 patients and is designed to compare the Resolute Integrity DES (Medtronic) versus Cre8™. Participants will be given 1 month DAPT in elective PCI and 12 months DAPT in ACS. Clinical follow up will be at 12 months and 3 years and will assess all MACE.
To end the presentation, Professor Stella presented a case of a 78-year-old man admitted for colon cancer, who suffered an ACS; an ECG showed inferolateral MI. Potential strategies included plain old balloon angioplasty (POBA), drug-eluting balloon (DEB) and implantation of a BMS or DES. The patient was treated with Cre8™ DES implantation and 4 weeks DAPT. At 4 weeks, OCT showed that all the struts were covered; therefore, the patient was referred for surgery and DAPT therapy was stopped. Six weeks later, an untreated residual stenosis was stented. The patient was doing well at clinical follow-up.
In conclusion, the Cre8™ polymer-free DES combines excellent efficacy with the safety associated with BMS, and offers the potential for reduced duration of DAPT. The ReCre8 study will further study the efficacy and safety of the Cre8™ stent with further reduced DAPT. n Source: Byrne, 2014. 10 
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